The overview discusses 58 peptides in different clinical phases, indicating a sturdy pipeline of peptide therapies focusing on PPIs. Any potential conflicts of interest, like funding from pharmaceutical firms or personal investments in relevant industries, are carefully disclosed during the research publications. This disclosure is vital to prot